research Ritlecitinib in severe alopecia areata: a profile of its use
Ritlecitinib effectively regrows hair in severe alopecia areata and is well tolerated.
Search
for
Sort by
Research
240-270 / 1000+ results research Cyproterone acetate and risk of meningioma: a nationwide cohort study
Taking high doses of Cyproterone acetate significantly increases the risk of meningioma in females.
research 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
CTP-543 is generally safe for treating alopecia areata.
research Liarozole—a novel treatment approach for advanced prostate cancer: results of a large randomized trial versus cyproterone acetate
Liarozole may be more effective than cyproterone acetate for treating advanced prostate cancer, with better PSA response and survival rates, while maintaining quality of life.
research Use of high dose cyproterone acetate and risk of intracranial meningioma in women: cohort study
High doses of cyproterone acetate increase the risk of brain tumors in women, but the risk decreases after stopping the medication.
research Pooled safety and tolerability data from four placebo-controlled teriflunomide studies and extensions
Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
research DRUG NEWS
The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.
research Physician Awareness of the Safe Use of Cyproterone Acetate in Europe: A Survey on the Effectiveness of Additional Risk Minimization Measures
Most European physicians know the risks and safe use of Cyproterone acetate, but few remember receiving official safety communications.
research Commonly prescribed medications associated with alopecia
Valproic acid, a common antiepileptic medication, can cause reversible hair loss in patients.
research Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
Ritlecitinib effectively treats alopecia areata with manageable side effects.
research Oral isotretinoin for acne
Oral isotretinoin may slightly improve acne but increases the risk of side effects like dry lips and skin; more research is needed to understand its full risks and benefits.
research Updated Integrated Safety Analysis of Ritlecitinib up to ~5 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
Ritlecitinib is generally safe for adolescents with alopecia areata over 5 years.
research Beyond Clinical Efficacy: A Literature Review on the Safety Challenges of Isotretinoin Therapy
Isotretinoin can safely and effectively control acne with proper risk management and monitoring.
research Midazolam Inhibits Hippocampal Long-Term Potentiation and Learning through Dual Central and Peripheral Benzodiazepine Receptor Activation and Neurosteroidogenesis
Midazolam impairs learning and memory by increasing neurosteroids through specific receptor activation.
research Vitamins
High doses of certain vitamins can cause serious side effects and health risks.
research GABAergic neurosteroids mediate the effects of ethanol on long‐term potentiation in rat hippocampal slices
Ethanol blocks memory formation in rats by enhancing certain brain chemicals.
research Follow‐up of Adverse Drug Reactions from Peginterferon alfa‐2b—Ribavirin Therapy
Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
research Effect of the allopregnanolone and allotetrahydrodeoxycorticosteron on spike-wave discharges in the EEG of absence epilepsy rat models
The steroids allopregnanolone and allotetrahydrodeoxycorticosteron worsened absence seizures in rats.
research Neurosteroids and Epileptogenesis
Neurosteroids may help prevent seizures and slow epilepsy progression.
research Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO ‐LT phase 3, open‐label study
Ritlecitinib is effective and safe for treating alopecia areata, promoting significant hair regrowth.
research Increased risk of telogen effluvium with tirzepatide compared to other weight-loss medications: a retrospective cohort TriNetX database study
research Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b–3 trial
Ritlecitinib effectively treats alopecia areata and is well-tolerated.
research The Shifting Landscape of Disease-Modifying Therapies for Relapsing Multiple Sclerosis
New treatments for relapsing multiple sclerosis are more effective and convenient but have higher risks of serious side effects.
research Long-Term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-Year Results from the ALLEGRO Phase 2b/3 and ALLEGRO-LT Phase 3 Clinical Studies
Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
research Valproic acid monotherapy induced longitudinal melanonychia
Valproic acid can cause dark lines on nails.
research Protein kinase C is a key target for attenuation of Leigh syndrome by rapamycin
Rapamycin may help treat Leigh syndrome by targeting protein kinase C.
research Cancer prevalence after exposure to Wnt-activating drugs: a systematic review
Wnt-activating drugs generally do not increase cancer risk.
research THU0189 Safety of four treatment regimens in early rheumatoid arthritis
All four treatments for early rheumatoid arthritis had similar safety profiles.
research HAIR LOSS ASSOCIATED WITH ESCITALOPRAM: DO SSRIs AFFECT MELATONIN AT THE HAIR FOLLICLE?
The antidepressant escitalopram likely caused hair loss in a patient.
research Systematic review and meta-analysis of the efficacy and safety of leflunomide and methotrexate in the treatment of rheumatoid arthritis
Leflunomide and methotrexate are equally effective for rheumatoid arthritis but have different side effects.